SG Americas Securities LLC Has $1.22 Million Position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

SG Americas Securities LLC lifted its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRXGet Rating) by 18.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 24,698 shares of the specialty pharmaceutical company’s stock after buying an additional 3,905 shares during the quarter. SG Americas Securities LLC’s holdings in Eagle Pharmaceuticals were worth $1,222,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the business. Comerica Bank raised its stake in shares of Eagle Pharmaceuticals by 12.1% in the first quarter. Comerica Bank now owns 9,980 shares of the specialty pharmaceutical company’s stock valued at $502,000 after acquiring an additional 1,080 shares during the last quarter. Exchange Traded Concepts LLC acquired a new stake in shares of Eagle Pharmaceuticals in the 1st quarter valued at approximately $1,476,000. Assenagon Asset Management S.A. increased its position in Eagle Pharmaceuticals by 68.5% during the first quarter. Assenagon Asset Management S.A. now owns 87,729 shares of the specialty pharmaceutical company’s stock worth $4,342,000 after buying an additional 35,649 shares during the last quarter. Strs Ohio bought a new position in shares of Eagle Pharmaceuticals in the first quarter valued at about $460,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Eagle Pharmaceuticals by 29.7% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,665 shares of the specialty pharmaceutical company’s stock valued at $132,000 after acquiring an additional 610 shares in the last quarter. Institutional investors own 88.71% of the company’s stock.

Eagle Pharmaceuticals Price Performance

Shares of NASDAQ:EGRX opened at $39.70 on Friday. Eagle Pharmaceuticals, Inc. has a 1 year low of $38.50 and a 1 year high of $58.25. The stock has a market capitalization of $505.74 million, a price-to-earnings ratio of 14.33 and a beta of 0.67. The company’s 50 day simple moving average is $44.25 and its 200 day simple moving average is $46.27.

Eagle Pharmaceuticals (NASDAQ:EGRXGet Rating) last posted its quarterly earnings results on Monday, May 9th. The specialty pharmaceutical company reported $3.41 EPS for the quarter, topping analysts’ consensus estimates of $3.19 by $0.22. The business had revenue of $115.87 million during the quarter, compared to analysts’ expectations of $122.39 million. Eagle Pharmaceuticals had a net margin of 14.56% and a return on equity of 18.56%. During the same period last year, the company posted ($0.03) earnings per share. As a group, analysts anticipate that Eagle Pharmaceuticals, Inc. will post 8.22 EPS for the current fiscal year.

About Eagle Pharmaceuticals

(Get Rating)

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.

Read More

Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRXGet Rating).

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.